Literature DB >> 31767710

No evidence of increased risk of acquired rifampin resistance.

Dick Menzies1, Victoria Cook2, Richard Long3, Rovina Ruslami4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31767710      PMCID： PMC6877362          DOI： 10.1503/cmaj.73353

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

Review 1.  Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Authors:  Nafees Ahmad; Shama D Ahuja; Onno W Akkerman; Jan-Willem C Alffenaar; Laura F Anderson; Parvaneh Baghaei; Didi Bang; Pennan M Barry; Mayara L Bastos; Digamber Behera; Andrea Benedetti; Gregory P Bisson; Martin J Boeree; Maryline Bonnet; Sarah K Brode; James C M Brust; Ying Cai; Eric Caumes; J Peter Cegielski; Rosella Centis; Pei-Chun Chan; Edward D Chan; Kwok-Chiu Chang; Macarthur Charles; Andra Cirule; Margareth Pretti Dalcolmo; Lia D'Ambrosio; Gerard de Vries; Keertan Dheda; Aliasgar Esmail; Jennifer Flood; Gregory J Fox; Mathilde Fréchet-Jachym; Geisa Fregona; Regina Gayoso; Medea Gegia; Maria Tarcela Gler; Sue Gu; Lorenzo Guglielmetti; Timothy H Holtz; Jennifer Hughes; Petros Isaakidis; Leah Jarlsberg; Russell R Kempker; Salmaan Keshavjee; Faiz Ahmad Khan; Maia Kipiani; Serena P Koenig; Won-Jung Koh; Afranio Kritski; Liga Kuksa; Charlotte L Kvasnovsky; Nakwon Kwak; Zhiyi Lan; Christoph Lange; Rafael Laniado-Laborín; Myungsun Lee; Vaira Leimane; Chi-Chiu Leung; Eric Chung-Ching Leung; Pei Zhi Li; Phil Lowenthal; Ethel L Maciel; Suzanne M Marks; Sundari Mase; Lawrence Mbuagbaw; Giovanni B Migliori; Vladimir Milanov; Ann C Miller; Carole D Mitnick; Chawangwa Modongo; Erika Mohr; Ignacio Monedero; Payam Nahid; Norbert Ndjeka; Max R O'Donnell; Nesri Padayatchi; Domingo Palmero; Jean William Pape; Laura J Podewils; Ian Reynolds; Vija Riekstina; Jérôme Robert; Maria Rodriguez; Barbara Seaworth; Kwonjune J Seung; Kathryn Schnippel; Tae Sun Shim; Rupak Singla; Sarah E Smith; Giovanni Sotgiu; Ganzaya Sukhbaatar; Payam Tabarsi; Simon Tiberi; Anete Trajman; Lisa Trieu; Zarir F Udwadia; Tjip S van der Werf; Nicolas Veziris; Piret Viiklepp; Stalz Charles Vilbrun; Kathleen Walsh; Janice Westenhouse; Wing-Wai Yew; Jae-Joon Yim; Nicola M Zetola; Matteo Zignol; Dick Menzies
Journal:  Lancet       Date:  2018-09-08       Impact factor: 79.321

2.  Responsible use of rifampin for the treatment of latent tuberculosis infection.

Authors:  Jane Batt; Kamran Khan
Journal:  CMAJ       Date:  2019-06-24       Impact factor: 8.262

3.  Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.

Authors:  Dick Menzies; Menonli Adjobimey; Rovina Ruslami; Anete Trajman; Oumou Sow; Heejin Kim; Joseph Obeng Baah; Guy B Marks; Richard Long; Vernon Hoeppner; Kevin Elwood; Hamdan Al-Jahdali; Martin Gninafon; Lika Apriani; Raspati C Koesoemadinata; Afranio Kritski; Valeria Rolla; Boubacar Bah; Alioune Camara; Isaac Boakye; Victoria J Cook; Hazel Goldberg; Chantal Valiquette; Karen Hornby; Marie-Josée Dion; Pei-Zhi Li; Philip C Hill; Kevin Schwartzman; Andrea Benedetti
Journal:  N Engl J Med       Date:  2018-08-02       Impact factor: 91.245

4.  Safety and Side Effects of Rifampin versus Isoniazid in Children.

Authors:  Thierno Diallo; Menonli Adjobimey; Rovina Ruslami; Anete Trajman; Oumou Sow; Joseph Obeng Baah; Guy B Marks; Richard Long; Kevin Elwood; David Zielinski; Martin Gninafon; Diah A Wulandari; Lika Apriani; Chantal Valiquette; Federica Fregonese; Karen Hornby; Pei-Zhi Li; Philip C Hill; Kevin Schwartzman; Andrea Benedetti; Dick Menzies
Journal:  N Engl J Med       Date:  2018-08-02       Impact factor: 91.245

5.  Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Authors:  Dick Menzies; Richard Long; Anete Trajman; Marie-Josée Dion; Jae Yang; Hamdan Al Jahdali; Ziad Memish; Kamran Khan; Michael Gardam; Vernon Hoeppner; Andrea Benedetti; Kevin Schwartzman
Journal:  Ann Intern Med       Date:  2008-11-18       Impact factor: 25.391

Review 6.  Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.

Authors:  Medea Gegia; Nicholas Winters; Andrea Benedetti; Dick van Soolingen; Dick Menzies
Journal:  Lancet Infect Dis       Date:  2016-11-17       Impact factor: 25.071

Review 7.  Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis.

Authors:  S den Boon; A Matteelli; H Getahun
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

Review 8.  Isoniazid preventive therapy and risk for resistant tuberculosis.

Authors:  Maria Elvira Balcells; Sara L Thomas; Peter Godfrey-Faussett; Alison D Grant
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883
  8 in total
  1 in total

1.  No evidence of increased risk of acquired rifampin resistance.

Authors: 
Journal:  CMAJ       Date:  2020-03-02       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.